Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.33 |
| ▸ | TP53 | P04637 | 8/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | HPGD | P15428 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23387630 | 0.87 | PTGS1 (0.39) | SMN1; SMN2TP53THRBRAB9ANPC1 | |
| SCHEMBL20229724 | 0.80 | TP53 (0.33) | SMN1; SMN2TP53THRBMAPT | |
| SCHEMBL17863729 | 0.77 | CYP19A1 (0.45) | SMN1; SMN2TP53RAB9ANPC1MAPT | |
| SCHEMBL17863733 | 0.76 | KDM1A (0.33) | SMN1; SMN2RAB9ANPC1MAPTALDH1A1 | |
| SCHEMBL17863720 | 0.75 | DAO (0.32) | — | |
| SCHEMBL17863728 | 0.73 | CCNE1 (0.31) | — | |
| SCHEMBL17863736 | 0.73 | LMNA (0.33) | KMT2A | |
| SCHEMBL17863730 | 0.73 | PKM (0.33) | — | |
| SCHEMBL14046214 | 0.71 | TP53 (0.34) | SMN1; SMN2TP53THRBMAPT | |
| SCHEMBL11326572 | 0.71 | KDM4E (0.42) | SMN1; SMN2MAPTALDH1A1HPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180155296-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2018-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180155296-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | ROCK1, MYLK, ROCK2 | SMN1; SMN2 1146/4885TP53 3738/4885THRB 410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.